Open AccessReducing Adverse Polypharmacy in Patients With Borderline Personality Disorder
Author(s) -
Alok Madan,
John M. Oldham,
S Espla Gonzalez,
J. Christopher Fowler
Publication year - 2015
Publication title -
primary care companion to cns disorders/the primary care companion for cns disorders
Language(s) - English
Resource type - Journals
eISSN - 2155-7772
pISSN - 2155-7780
DOI - 10.4088/pcc.14m01760
Subject(s) - polypharmacy , borderline personality disorder , context (archaeology) , psychiatry , medicine , impulsivity , anxiety , adverse effect , personality , clinical psychology , psychology , intensive care medicine , paleontology , social psychology , biology
Polypharmacy is common and especially challenging in the context of borderline personality disorder in light of impulsivity and self-harm associated with the disorder, risk of adverse drug-drug interactions, and financial burden. Reduction in polypharmacy could be conceptualized as a high priority in the treatment of borderline personality disorder. This case aims to demonstrate that potential.